A balancing act--making the right choices in anti-inflammatory drug development

Curr Opin Investig Drugs. 2007 May;8(5):362-3.
No abstract available

Publication types

  • Editorial
  • Review

MeSH terms

  • Administration, Oral
  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Drug Delivery Systems
  • Drug Design*
  • Humans
  • Integrin alpha4 / metabolism
  • Leukocytes / drug effects
  • Leukocytes / metabolism
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / metabolism
  • Natalizumab
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Natalizumab
  • Integrin alpha4